Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression?

Abstract

Background: Subsyndromal symptoms of depression (SSD) in patients with schizophrenia are common and clinically important. While treatment of depression in major depressive disorder may partially ameliorate cognitive deficits, the cognitive effects of antidepressant medications in patients with schizophrenia or schizoaffective disorder and SSD are unknown. Methods: The goal of this study was to assess the impact of SSD and their treatment on cognition in participants with schizophrenia or schizoaffective disorder aged ≧40 years. Participants were randomly assigned to a flexible dose treatment with citalopram or placebo augmentation of their current medication for 12 weeks. An ANCOVA compared improvement in the cognitive composite scores, and a linear model determined the moderation of cognition on treatment effects based on the Hamilton Depression Rating Scale and the Calgary Depression Rating Scale scores between treatment groups. Results: There were no differences between the citalopram and placebo groups in changes in cognition. Baseline cognitive status did not moderate antidepressant treatment response. Conclusions: Although there are other cogent reasons why SSD in schizophrenia warrant direct intervention, treatment does not substantially affect the level of cognitive functioning. Given the effects of cognitive deficits associated with schizophrenia on functional disability, there remains an ongoing need to identify effective means of directly ameliorating them.

The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: A systematic review and meta-analysis

“…anxiety, insomnia and pain (Wong et al, 2016). Several studies (Chen et al, 2013;Han et al, 2011;Herrera-Guzman et al, 2010;Jorge et al, 2010;Nair et al, 2014;Rozzini et al, 2010) have shown behavioral and cognitive improvement associated with antidepressant drug usage in patients with a range of neurologic and psychiatric diagnoses, although the literature also provides instances that might question any beneficial effect of antidepressant drug usage in cognitive decline (Ardal & Hammar, 2011;Dawes et al, 2012;Kessing, Forman, & Andersen, 2011;Rosenberg et al, 2012). The possibility that these drugs might not benefit all patient populations and actually could be contributing to risk of iatrogenic cognitive decline (i.e.…”

Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review

“…Using our search criteria, we identified one RCT on citalopram. In this 12‐week study of 198 patients with schizophrenia, it was found that there were no significant differences between citalopram (20 mg/day) and placebo in changes in cognition 48 . To assess patients' cognition, a test battery was used which included the MMSE, Digit Span Distractibility Test, Letter and Category Fluency, Trail‐Making Test, CPT, Digit‐Symbol‐Coding, Symbol Search, and Letter‐Number Sequencing.…”

“…In this 12-week study of 198 patients with schizophrenia, it was found that there were no significant differences between citalopram (20 mg/day) and placebo in changes in cognition. 48…”

Does the Use of Antidepressants Accelerate the Disease Progress in Creutzfeldt–Jakob Disease Patients With Depression? A Case Report and A Systematic Review

“…Many reasons lie behind the prescription of antidepressant drugs, which increased dramatically from 1999 to 2014 (5). However, some studies have questioned whether antidepressants confer any benefits in terms of cognitive decline (6–9). Recently, a meta-analysis indicated that antidepressant usage was associated with AD/dementia (10).…”